Alexandra Glucksmann is the founder of Cedilla Therapeutics. Cedilla Therapeutics has raised $83M in total funding. Latest round: Series B.
Alexandra Glucksmann is the President and Chief Executive Officer of Cedilla Therapeutics, a biotechnology company focused on precision oncology. Cedilla Therapeutics is developing small molecules to selectively inhibit oncogenic drivers by conditionally modulating proteins in their functional state. The company has raised a total of $82.6 million in Series B financing, with funding from investors including RA Capital Management, Janus Henderson Investors, Woodline Partners LP, Logos Capital, and Third Rock Ventures.
Full founder directory · Investor directory · Company funding database · Fundraising library